- Home
- KURA vs PRDO Comparison
KURA vs PRDO Comparison
Compare KURA & PRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- PRDO
- Stock Information
- Founded
- KURA 2014
- PRDO 1994
- Country
- KURA United States
- PRDO United States
- Employees
- KURA N/A
- PRDO N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- PRDO Other Consumer Services
- Sector
- KURA Health Care
- PRDO Real Estate
- Exchange
- KURA Nasdaq
- PRDO Nasdaq
- Market Cap
- KURA 793.2M
- PRDO N/A
- IPO Year
- KURA N/A
- PRDO N/A
- Fundamental
- Price
- KURA $7.26
- PRDO $26.78
- Analyst Decision
- KURA Strong Buy
- PRDO Buy
- Analyst Count
- KURA 11
- PRDO 1
- Target Price
- KURA $27.89
- PRDO $32.00
- AVG Volume (30 Days)
- KURA 1.8M
- PRDO 456.9K
- Earning Date
- KURA 02-25-2025
- PRDO 02-19-2025
- Dividend Yield
- KURA N/A
- PRDO 1.82%
- EPS Growth
- KURA N/A
- PRDO N/A
- EPS
- KURA N/A
- PRDO 1.99
- Revenue
- KURA N/A
- PRDO $652,751,000.00
- Revenue This Year
- KURA N/A
- PRDO N/A
- Revenue Next Year
- KURA $233.30
- PRDO $2.27
- P/E Ratio
- KURA N/A
- PRDO $13.42
- Revenue Growth
- KURA N/A
- PRDO N/A
- 52 Week Low
- KURA $6.98
- PRDO $16.12
- 52 Week High
- KURA $24.17
- PRDO $29.47
- Technical
- Relative Strength Index (RSI)
- KURA 17.38
- PRDO 54.64
- Support Level
- KURA $6.98
- PRDO $25.48
- Resistance Level
- KURA $8.88
- PRDO $26.63
- Average True Range (ATR)
- KURA 0.33
- PRDO 0.63
- MACD
- KURA 0.05
- PRDO -0.04
- Stochastic Oscillator
- KURA 13.40
- PRDO 93.51
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.